FDG PET/MR 影像联合配准有助于预测胶质母细胞瘤标准治疗后影像学进展患者的生存期
回顾性分析56例胶质母细胞瘤患者,术后同步放化疗后随访MR显示影像学恶化时行FDG PET/CT,计算残留病灶SUVr。SUVr<1.7组中位生存23.1个月,显著长于SUVr 2.0~<2.5组的10.1个月和SUVr≥2.5组的7.5个月;总生存与SUVr显著相关(P=.006)。
要点
- 标准治疗后MR疑进展的胶质母细胞瘤,残留病灶FDG摄取越高生存越短。
- SUVr<1.7者中位生存23.1个月,SUVr 2.0~<2.5者10.1个月,SUVr≥2.5者7.5个月。
- SUVr以肿瘤SUVmax相对健康白质计算,用于分层预测生存。
核心结论
- 标准治疗后MR显示残留病灶且FDG PET相对代谢活性高的胶质母细胞瘤患者,生存时间短于FDG PET低活性者。
研究设计与样本
- 回顾性研究,纳入2006年至2015年间56例胶质母细胞瘤患者,均接受术后同步放疗和替莫唑胺治疗,因随访MR影像学恶化而行FDG PET/CT。
- 计算残留病灶代谢活性标准化指标SUVr,即肿瘤SUVmax相对健康白质;主要终点为自PET起的生存时间,按SUVr分层,用Cox比例风险模型的对数风险比比较亚组死亡风险。
关键影像表现/征象
- 在随访MR显示残留病灶的基础上,FDG PET测得该残留病灶的相对代谢活性(SUVr)与总生存显著相关(P=.006)。
诊断标准与关键数值
- SUVr<1.7组中位生存23.1个月(95%CI:12.7,38.9),显著长于SUVr 2.0~<2.5组的10.1个月(95%CI:2.4,15.9;P=.008)。
- SUVr<1.7组中位生存23.1个月(95%CI:12.7,38.9),显著长于SUVr≥2.5组的7.5个月(95%CI:3.9,9.7;P<.001)。
临床应用与阅片要点
- 对标准治疗后MR疑进展的胶质母细胞瘤,可结合FDG PET测量的残留病灶SUVr评估预后,SUVr<1.7者生存较长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine the correlation between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in patients with glioblastoma and suspected progression at posttherapy magnetic resonance (MR) imaging. Materials and Methods The authors retrospectively examined the relationship between metabolic activity at FDG PET in the residual lesion identified at brain MR imaging and survival time in 56 patients with glioblastoma who were treated with postoperative concurrent radiation and temozolomide therapy and who underwent FDG PET/computed tomography because of radiologic deterioration at follow-up MR imaging between 2006 and 2015. A normalized metric of metabolic activity in the residual lesion (standardized uptake value ratio [SUVr]) was calculated as the maximum standardized uptake value (SUVmax) in the tumor relative to that in healthy white matter. The primary end point of the study was survival time from PET. Patients were stratified according to SUVr. Comparisons of risk for death between subgroups were made with the log-hazard ratio of the Cox proportional hazard model. Results There was a significant association between overall survival and SUVr in the residual lesion (P = .006), and a survival benefit was observed in patients with SUVr of less than 1.7, who had a median survival time of 23.1 months (95% confidence interval [CI]: 12.7, 38.9), which was significantly longer than that in patients with an SUVr of 2.0 to less than 2.5 and those with an SUVr of at least 2.5, who had a median survival time of 10.1 (95% CI: 2.4, 15.9; P = .008) and 7.5 (95% CI: 3.9, 9.7; P < .001) months, respectively. Conclusion Patients with glioblastoma whose posttherapy MR images showed a residual lesion with high relative metabolic activity at FDG PET had a shorter survival time than did those with low activity at FDG PET. © RSNA, 2016.
引用
- Leiva-Salinas C, Schiff D, Flors L, et al. FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment. Radiology. 2016. PMID: 28234553. doi:10.1148/radiol.2016161172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。